熱門資訊> 正文

木薯科学GAAP每股收益为-0.92美元

2025-08-14 19:41

Cassava Sciences press release (NASDAQ:SAVA): Q2 GAAP EPS of -$0.92.
Cash and cash equivalents were $112.4 million, with no debt, as of June 30, 2025. This compares to cash and cash equivalents of $128.6 million as of December 31, 2024.

More on Cassava Sciences

Cassava Sciences taps Joseph Hulihan as chief medical officer
Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit
Financial information for Cassava Sciences

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。